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Abstract
Background: It is estimated that approximately half of the deaths in patients with HF are sudden and that the most likely
causes of sudden death are lethal ventricular tachyarrhythmias such as ventricular tachycardia (VT) or fibrillation (VF).
However, the precise mechanism of ventricular tachyarrhythmias remains unknown. The KCNH2 channel conducting the
delayed rectifier K
+ current (IKr) is recognized as the most susceptible channel in acquired long QT syndrome. Recent
findings have revealed that not only suppression but also enhancement of IKr increase vulnerability to major arrhythmic
events, as seen in short QT syndrome. Therefore, we investigated the existence of a circulating KCNH2 current-modifying
factor in patients with HF.
Methodology/Principal Findings: We examined the effects of serum of HF patients on recombinant IKr recorded from HEK
293 cells stably expressing KCNH2 by using the whole-cell patch-clamp technique. Study subjects were 14 patients with
non-ischemic HF and 6 normal controls. Seven patients had a history of documented ventricular tachyarrhythmias (VT: 7 and
VF: 1). Overnight treatment with 2% serum obtained from HF patients with ventricular arrhythmia resulted in a significant
enhancement in the peaks of IKr tail currents compared to the serum from normal controls and HF patients without
ventricular arrhythmia.
Conclusions/Significance: Here we provide the first evidence for the presence of a circulating KCNH2 channel activator in
patients with HF and ventricular tachyarrhythmias. This factor may be responsible for arhythmogenesis in patients with HF.
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Introduction
Heart failure (HF) remains a major clinical problem all over the
world.[1] It is estimated that approximately half of the deaths in
these patients is sudden and that the most likely causes of sudden
cardiac death (SCD) are lethal cardiac arrhythmia such as
ventricular tachycardia (VT) or fibrillation (VF).[2] It has been
known for a long time that the failing heart undergoes a complex
electrical remodeling of ventricular myocytes and that a
consequent reduction of repolarization reserve and electrical
instability may predispose to an increased risk of life-threatening
arrhythmia.[3,4]
KCNH2, also called human ether-a-go-go-related gene (hERG)
potassium channel, is responsible for the rapid components of
delayed rectifier potassium currents (IKr). IKr is a major contributor
to the repolarization process of cardiac action potentials and is
recognized as the most susceptible channel in acquired long QT
syndrome.[5] Recent findings have revealed that not only
suppression but also enhancement of IKr increase vulnerability to
major arrhythmic events. A gain-of-function mutation in KCNH2
has also gained recognition as a congenital disorder characterized
bya higherriskformajorarrhythmiceventsand SCD,referredtoas
short QT syndrome (SQT).[6,7] It has also been reported that PD-
118057, an IKr-activating agent, predisposes to cardiac arrhythmias
in vitro.[8] HF also induces remodeling of IKr, but there is no
widespread consensus on suppression or enhancement of IKr in
previous studies.[9,10] Furthermore, despite the incremental
progress in understanding intrinsic IKr modulators, to our
knowledge, there has been no report of naturally occurring
substances with a KCNH2 current-activating effect in patients with
HF. Therefore, we investigated the existence of a circulating
KCNH2 current-activating factor in patients with HF.
Results
Characteristics of the study subjects
Demographics and selected clinical characteristics of the HF
patients are summarized in Table 1. The etiology of HF in the
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coarditis (n=3), dilated hypertrophic cardiomyopathy (n=1),
tachycardia-induced cardiomyopathy (n=1) and apical ballooning
syndrome (n=1). Ventricular tachyarrhythmias were documented
in 8 patients: non-sustained VT in 4 (50%), sustained VT in 3
(38%) and VF in 1 (13%). There were no significant differences in
the mean age between the control group, the HF without VT and
VF (VT/VF (2)) group, and the HF with VT and VF (VT/VF (+))
group (42.7614.8 yrs, 50.7610.9 yrs and 53.3610.8 yrs, respec-
tively; P=0.28). Male-to-female ratio was also not significantly
different between the groups (2:1, 2:1 and 1:1 for the control, VT/
VF (2) and VT/VF (+) groups, respectively; P=0.76). Mean QTc
interval was longer in the overall HF patients than in the controls
(0.4660.03 sec
1/2 vs. 0.42 6 0.03 sec
1/2; P,0.05), but there was
no significant difference between the VT/VF (2) and VT/VF (+)
groups (0.4560.03 sec
1/2 vs. 0.4760.02 sec
1/2; P=0.51). Mean
left ventricular ejection fraction (EF) was similar in the VT/VF (2)
and VT/VF (+) groups (39611% vs. 31613%, P=0.22).
More than half of the patients in the VT/VF (+) group took
cardiotonic agents, whereas none of the patients in the VT/VF (2)
group took cardiotonic agents (Table 2). However, none of the
drugs, including cardiotonic agents, taken by the subjects have
been reported to activate KCNH2 current.
Enhancement of KCNH2 currents by serum from HF
patients with ventricular tachyarrhythmia
We investigated the effect of 2% serum of the study subjects on
recombinant IKr recorded from HEK293 cells stably expressing
KCNH2. KCNH2 tail currents were similar in the control and
VT/VF (2) group but were significantly increased in the VT/VF
(+) group (P,0.05: VT/VF (+) vs. control and VT/VF (2))
(Figure 1). There was no significant effect on voltage dependency
of KCNH2 activation in these groups (Table 3). There was no
relationship between peak tail amplitude and EF in the overall HF
patients (Figure 2).
These results indicate the presence of a circulating KCNH2
channel activator in patients with HF and ventricular tachyar-
rhythmias.
Efficacy of class III antiarrhythmic agents
Case No.1 was treated with amiodarone, and Case No.6 was
treated with d-sotalol. Both drugs, which exert their antiarrhyth-
mic actions essentially by blocking IKr,were effective in controlling
VT and VF.
Discussion
The major new finding of this work is that the factor causing
activation of the KCNH2 current is present in serum of patients
with HF accompanied by cardiac arrhythmia. Although there are
several reports on suppression of IKr by circulating hormones or
auto-antibodies, this is the first report providing evidence for a
naturally occurring IKr activator.[5,11,12] IKr conducted by
KCNH2 channels is the major repolarizing outward current of
ventricular action potential, and it has been shown to have a strong
association with life-threatening arrhythmia in many pathological
circumstances. Our finding indicates that enhancement of IKr can
play a key role in arrhythmogenesis in the setting of HF.
The majority of research efforts have focused classically on
reduction of IKr as an approach for understanding arrhtymogen-
esis because it is well recognized that reduction of Ikr means
decrease in net repolarizing current that results in prolongation of
action potential duration (APD) and QT interval in the ECG and
development of early afterdepolarization-induced triggered activ-
ity following torsade de pointes (TdP).[13] On the other hand,
much attention has been paid to upregulation of KCNH2 in
recent years because of its causal relationship to cardiac
arrhythmias. SQT is a recently recognized clinical concept
characterized by short QT intervals in the ECG, and it is
associated with major cardiac events leading to SCD without
organic heart disease.[7] The first identified form of SQT resulted
from gain-of-function mutation in KCNH2. Mutation N588K in
KCNH2 causes an increase in net repolarizing current.[6] In
addition, recent studies have revealed a significant association
between early repolarization and SQT in clinical pheno-
type.[14,15] Because of the high prevalence of early repolarization
detected in SQT, it is thought that enhancement of repolarization
is a common mechanism underlying arryhthmogenicity in early
Table 1. Clinical characteristics of the study population.
Case No. Age/Sex Diagnosis NYHA LVEF (%) Arrhythmia QTc (sec
1/2)
1 73/F myocarditis II 50 sustained VT 0.46
2 45/M DCM II 11 NSVT 0.47
3 55/F dilated-HCM IV 25 NSVT 0.47
4 37/F DCM III 19 sustained VT 0.48
5 61/F DCM II 37 NSVT 0.43
6 52/M myocarditis II 42 VF 0.45
7 48/M Tachycardia-induced cardiomyopathy II 24 NSVT 0.48
8 64/F Apical ballooning syndrome II 47 none 0.43
9 61/F myocarditis II 42 none 0.48
10 45/M DCM II 50 none 0.39
11 55/M DCM III 40 sustained VT 0.51
12 37/M DCM II 40 none 0.47
13 55/M DCM II 38 none 0.47
14 42/M DCM II 20 none 0.46
NYHA: New York Heart Association Functional Classification, LVEF: left ventricular ejection fraction, DCM: idiopathic dilated cardiomyopathy, HCM: hypertrophic
cardiomyopathy, VT: ventricular tachycardia, NSVT: non-sustained ventricular tachycardia, VF: ventricular fibrillation, QTc: corrected QT interval
doi:10.1371/journal.pone.0019897.t001
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other ion channels and cardiac enlargement, QT interval of HF
patients with ventricular tachyarrhythmia in this study was not
short. However, the circulating KCNH2 channel activator in this
study is potentially responsible for electrical instability.
Effects of KCNH2-activating agents have also been evaluated.
It has been reported that PD-118057, established as a selective
KCNH2 current enhancer without affecting activation, confers
inducibility of both ventricular tachyarrhythmia and atrial
fibrillation.[8,16] The functional similarity between this agent
and circulating KCNH2-activating factor in having no significant
effect on the voltage dependence of activation suggests a causal
relationship of this intrinsic enhancer with arrhythmogenesis in
HF. In addition, this concept is endorsed by the efficacy of class III
antiarrhythmic agents for treatment of ventricular tachyarrhyth-
mia in the study subjects. Since the dominant action of class III
antiarrhythmic agents is to lengthen the APD by a reduction of
IKr, it is thought that the therapeutic effect of the agents against
arrhythmia in the study subjects is manifested by offsetting
oversupplied KCNH2 currents.
On the other hand, there are only a few reports on the
antiarrhythmic potential of an IKr activator in specialized
pathologic settings. PD-118057 prevented the early after-depolar-
ization induced by class III antiarrhythmic agents, and NS3623
decreased the frequency of bradycardia-induced extrasystoles in
vitro.[17,18] However, these data were obtained only in con-
strained experimental conditions and couldn’t refer clinical benefit
for arrhythmogenic disorders such as long QT syndrome.
The mechanism by which exposure of ion channels to this factor
activates the KCNH2 current remains to be elucidated. It is also
uncertain whether the KCNH2-activating effect is the cause or
consequence of HF-induced remodeling of action potential.
However, exertion of their functional effects may be involved in
arrhythmogenesis in HF. Further studies are needed to clarify
these points.
In conclusion, our data show that a novel KCNH2 activator
exists in serum of HF patients with ventricular tachyarrhythmia
and is potentially responsible for electrical instability.
Methods
All of the studies were approved by the Ethics Committee of
Okayama University Graduate School of Medicine, Dentistry, and
Pharmaceutical Sciences, and written informed consent was
obtained from all patients before the procedure. The investigation
also conforms to the principles outlined in the Declaration of
Helsinki.
Study population
Serum samples were obtained from 14 HF patients referred to
Okayama University Hospital, Okayama, Japan between Decem-
ber 2007 and December 2008 who consented to undergo
evaluation of the pathogenesis of HF. HF was defined as the
presence of current or previous symptoms of exercise intolerance
and EF of 50% and less with no other cause of exercise
intolerance. Exclusion criteria included coronary heart disease,
primary valvular heart disease, severe systemic disease, or severe
pulmonary disease. The mean age of the patients was 52610
years, and 8 patients (57%) were male. Control sera were obtained
from 6 subjects without cardiovascular disease or abnormal ECG
Table 2. Patient’s medication.
Case No. Medications
Antiarrhythmics Beta- blockers Diuretics ACEI/ARB
Anticoagulant/
Antiplatelet Cardiotonic others
1 amiodarone carvedilol torasemide candesartan none none none
2 none carvedilol furosemide
spironolactone
valsartan none pimobendan nateglinide, acarbose






4 amiodarone carvedilol torasemide losartan warfarin dopamine
dobutamine
none
5 none carvedilol furosemide candesartan warfarin none alfacalcidol
6 sotalol carvedilol none candesartan warfarin none potassium chloride, famotidine
7 none carvedilol furosemide
spironolactone
valsartan warfarin metildigoxin lansoprazole
8 none none none losartan aspirin none nifedipine, famotidine,
atorvastatin, icosapentate
9 none carvedilol furosemide
spironolactone
losartan warfarin none rabeprazole, ferrous citrate
10 none none none none none none none
11 none carvedilol torasemide
trichlormethiazide
candesartan warfarin metildigoxin pravastatin
12 none carvedilol none candesartan none none amlodipine





14 none carvedilol furosemide telmisartan warfarin none amlodipine
ACEI/ARB: Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers.
doi:10.1371/journal.pone.0019897.t002
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subjects (67%) were male.
Patch-clamp recordings
KCNH2 channel currents were recorded at room temperature
(2261uC) by using the whole-cell patch-clamp technique as
previously described.[11] The control bath solution contained
(mM): 132 NaCl, 4.8 KCl, 1.2 MgCl2, 2 CaCl2, 5 glucose, 10
Hepes, pH 7.4. Pipettes (2–4 MV resistances) were filled with a
pipette solution containing (mM): 110 potassium aspartate, 5 K2-
ATP, 11 EGTA, 5 Hepes, 1 CaCl2, and 1 MgCl2, pH 7.3.
Currents were normalized to cell capacitance to give the measure
of current density. There was no difference in membrane
capacitance between the groups (14.162.0 pF, 14.262.8 pF,
and 14.761.6 pF for the control, VT/VF (2) and VT/VF (+)
groups, respectively; P=0.88). KCNH2 channel tail-current
amplitude was monitored at 0.1 Hz by analysis of peak
deactivating tail current recorded at 240 mV after 2-s depolar-
izing test pulses to +20 mV from a holding potential (VH)o f
280 mV. Current zero level (no activation) was determined by
applying 25-ms pulses to 240 mV preceding the test pulses.
HEK293 cells stably expressing KCNH2 were cultured for 1 day
Figure 1. Effect of serum obtained from HF patients with ventricular tachyarrhythmia on KCNH2 currents in HEK 293 cells. A.
Representative traces from a single cell cultured in a medium supplemented with 2% serum of a control subject (left) and medium supplemented
with 2% serum of a patient with sustained VT (Case No. 1) (right). B. Current-voltage relationships of KCNH2 tail currents. Mean values of peak KCNH2
tail current densities were calculated by averaging the tail amplitude of each subject obtained from cells (n=8 to 11 cells) exposed to respective sera.
Open circles show the results for controls (n=6), open squares show the results for HF patients without VT and VF (VT/VF (2), n=6) and closed
squares show the results for HF patients with VT/VF (VT/VF (+), n=8). *P,0.05: VT/VF (+) vs. control and VT/VF (2). C. Maximum values of peak tail
current in the groups. *P,0.05: VT/VF (+) vs. control and VT/VF (2). NS indicates not significant.
doi:10.1371/journal.pone.0019897.g001
Figure 2. Relationship between peak tail amplitude and
ejection fraction in the overall HF patients.
doi:10.1371/journal.pone.0019897.g002
Table 3. Changes in voltage dependence of the KCNH2
activation.
Controls VT/VF(2) VT/VF(+) P
V1/2 (mV) 5.664.8 3.763.5 4.362.5 NS
Slope factor (k)8 . 2 60.8 8.260.9 8.661.0 NS
VT/VF (2): HF patients without VT and VF, VT/VF (+): HF patients with VT and VF
NS indicates not significant.
doi:10.1371/journal.pone.0019897.t003
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had been added. The KCNH2 current activation was studied by
analysis of deactivating tail currents recorded at 240 mV after a
series of 2-s test pulses from 250 mV to +70 mV (10 mV
increments; VH, 280 mV). Pulse frequency was 0.1 Hz. Peaks of
tail currents were plotted as function of the KCNH2 activation.
Activation curves were analyzed with a fit of each data to the
Boltzmann equation, I/Imax=G/Gmax={1+exp[2(Vm2V1/2)/
k]}
21. G/Gmax is normalized chord conductance at Vm to the
maximum chord conductance. V1/2 is the potential where the
conductance is half-maximally activated, and k is the slope factor.
ECG measurements
Twelve-lead ECGs were recorded to measure the parameters of
repolarization. The QT interval was measured from the start of
the QRS complex to the end of the T wave, defined as the return
to the iso-electric baseline. They were corrected to heart rate using
Bazett’s formula: QTc (QT/!RR).
Data Analysis
All values are presented as means6.D. Statistical significance
was assessed with ANOVA followed by post hoc Scheffe’s method.
A value of P,.05 was considered statistically significant. pCLAMP
9.2 software (Axon Instruments) was used to both acquire and
analyze data for the patch-clamp experiments. Graphical analyses
were carried out using Origin 7.0 J software (Microcal). Statistical
analysis was performed with StatView 5.0 (Abacus Concepts, Inc.,
Berkeley, CA, U.S.A.).
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